4,156 Shares in Abbott Laboratories (NYSE:ABT) Bought by Campbell & CO Investment Adviser LLC

Campbell & CO Investment Adviser LLC bought a new position in Abbott Laboratories (NYSE:ABT) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 4,156 shares of the healthcare product maker’s stock, valued at approximately $348,000.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Cumberland Partners Ltd grew its holdings in shares of Abbott Laboratories by 25.0% during the second quarter. Cumberland Partners Ltd now owns 4,500 shares of the healthcare product maker’s stock valued at $378,000 after buying an additional 900 shares in the last quarter. DekaBank Deutsche Girozentrale boosted its position in Abbott Laboratories by 91.4% during the second quarter. DekaBank Deutsche Girozentrale now owns 1,454,239 shares of the healthcare product maker’s stock valued at $122,138,000 after purchasing an additional 694,262 shares during the last quarter. Cypress Capital Management LLC boosted its position in Abbott Laboratories by 2.0% during the second quarter. Cypress Capital Management LLC now owns 203,419 shares of the healthcare product maker’s stock valued at $17,108,000 after purchasing an additional 4,000 shares during the last quarter. Genovese Burford & Brothers Wealth & Retirement Plan Management LLC boosted its position in Abbott Laboratories by 3.8% during the second quarter. Genovese Burford & Brothers Wealth & Retirement Plan Management LLC now owns 3,176 shares of the healthcare product maker’s stock valued at $267,000 after purchasing an additional 116 shares during the last quarter. Finally, Cresset Asset Management LLC boosted its position in Abbott Laboratories by 20.7% during the second quarter. Cresset Asset Management LLC now owns 29,187 shares of the healthcare product maker’s stock valued at $2,455,000 after purchasing an additional 5,012 shares during the last quarter. Institutional investors and hedge funds own 73.76% of the company’s stock.

In other Abbott Laboratories news, CFO Brian B. Yoor sold 43,763 shares of the business’s stock in a transaction dated Thursday, August 8th. The stock was sold at an average price of $85.77, for a total value of $3,753,552.51. Following the completion of the sale, the chief financial officer now owns 125,781 shares of the company’s stock, valued at $10,788,236.37. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Randel William Woodgrift sold 65,000 shares of the business’s stock in a transaction dated Wednesday, July 24th. The stock was sold at an average price of $88.01, for a total value of $5,720,650.00. Following the completion of the sale, the insider now directly owns 117,562 shares of the company’s stock, valued at approximately $10,346,631.62. The disclosure for this sale can be found here. Insiders sold 181,497 shares of company stock valued at $15,701,810 in the last ninety days. Insiders own 0.70% of the company’s stock.

ABT has been the subject of a number of research reports. ValuEngine cut Abbott Laboratories from a “buy” rating to a “hold” rating in a research report on Wednesday, October 2nd. BMO Capital Markets lifted their price objective on Abbott Laboratories from $87.00 to $94.00 and gave the company an “outperform” rating in a research report on Thursday, July 18th. Jefferies Financial Group lifted their price objective on Abbott Laboratories from $80.00 to $98.00 and gave the company a “buy” rating in a research report on Thursday, July 18th. Raymond James reduced their price objective on Abbott Laboratories from $93.00 to $90.00 and set an “outperform” rating for the company in a research report on Monday, October 14th. Finally, Credit Suisse Group lifted their price objective on Abbott Laboratories from $95.00 to $98.00 and gave the company an “outperform” rating in a research report on Thursday. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and thirteen have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $87.61.

Shares of NYSE:ABT opened at $82.79 on Friday. Abbott Laboratories has a fifty-two week low of $65.44 and a fifty-two week high of $88.76. The business has a 50-day moving average of $82.87 and a two-hundred day moving average of $81.76. The stock has a market capitalization of $145.60 billion, a P/E ratio of 28.75, a P/E/G ratio of 2.31 and a beta of 1.13. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.68 and a quick ratio of 1.20.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings results on Wednesday, October 16th. The healthcare product maker reported $0.84 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.84. Abbott Laboratories had a return on equity of 17.76% and a net margin of 10.50%. The company had revenue of $8.08 billion during the quarter, compared to analysts’ expectations of $8.10 billion. During the same quarter in the previous year, the firm earned $0.75 earnings per share. The business’s quarterly revenue was up 5.5% compared to the same quarter last year. As a group, research analysts expect that Abbott Laboratories will post 3.25 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Friday, November 15th. Shareholders of record on Tuesday, October 15th will be given a $0.32 dividend. The ex-dividend date is Friday, October 11th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 1.55%. Abbott Laboratories’s dividend payout ratio is currently 44.44%.

Abbott Laboratories Company Profile

Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The company's Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptom; gynecological disorder; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraine; and anti-infective clarithromycin, as well as provides influenza vaccines and products that regulate physiological rhythm of the colon.

Featured Story: What is an inverted yield curve?

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.